Literature DB >> 22132027

Identifying the aetiology of left ventricular hypertrophy in an athlete: importance of lifestyle modification.

Miriam Jane Ball1, Niall Keenan, Mary Lynch, Sanjay Prasad, Diana A Gorog.   

Abstract

The aetiology of left ventricular hypertrophy (LVH) in an athlete is often difficult to identify. We describe a 29-year-old fitness instructor who was referred for investigation of syncope. He gave a history of intensive weight lifting and anabolic steroid use at supra-therapeutic doses for the preceding 6 years. Electrocardiography showed inferolateral repolarisation abnormalities and a transthoracic echocardiogram demonstrated asymmetrical LVH with reduced left ventricular cavity dimensions. There was no left ventricular outflow tract obstruction or systolic motion of the anterior mitral valve leaflet. These findings were confirmed on cardiac magnetic resonance imaging (CMR). The differential diagnosis included athlete's heart, steroid-induced cardiomyopathy and non-obstructive hypertrophic cardiomyopathy. The patient was advised to discontinue both steroid use and intensive training. After 3 years of steroid abstinence but continued training, the syncopal episodes and the ECG abnormalities completely resolved, associated with regression of LVH on echocardiography and CMR.

Entities:  

Year:  2009        PMID: 22132027      PMCID: PMC3028985          DOI: 10.1136/bcr.10.2008.1080

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Left ventricular hypertrophy as a predictor of cardiovascular risk.

Authors:  Philippe Gosse
Journal:  J Hypertens Suppl       Date:  2005-04

2.  Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis.

Authors:  Antonello D'Andrea; Pio Caso; Gemma Salerno; Raffaella Scarafile; Giuseppe De Corato; Claudia Mita; Giovanni Di Salvo; Sergio Severino; Sergio Cuomo; Biagio Liccardo; Nicolino Esposito; Raffaele Calabrò
Journal:  Br J Sports Med       Date:  2006-12-18       Impact factor: 13.800

Review 3.  Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study.

Authors:  D Levy
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Reversible obstructive hypertrophic cardiomyopathy after dexamethasone therapy for bronchopulmonary dysplasia.

Authors:  B L Ohning; D A Fyfe; P A Riedel
Journal:  Am Heart J       Date:  1993-01       Impact factor: 4.749

5.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles.

Authors:  B J Maron; J Shirani; L C Poliac; R Mathenge; W C Roberts; F O Mueller
Journal:  JAMA       Date:  1996-07-17       Impact factor: 56.272

6.  Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?

Authors:  A Urhausen; T Albers; W Kindermann
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

7.  Anabolic steroid abuse and cardiac death.

Authors:  M C Kennedy; C Lawrence
Journal:  Med J Aust       Date:  1993-03-01       Impact factor: 7.738

8.  Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.

Authors:  B De Piccoli; F Giada; A Benettin; F Sartori; E Piccolo
Journal:  Int J Sports Med       Date:  1991-08       Impact factor: 3.118

9.  Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.

Authors:  Eduardo Payá; Francisco Marín; Josefa González; Juan Ramón Gimeno; Eloísa Feliu; Antonio Romero; Francisco Ruiz-Espejo; Vanessa Roldán; Vicente Climent; Gonzalo de la Morena; Mariano Valdés
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

10.  Marked left ventricular hypertrophy mimicking hypertrophic cardiomyopathy associated with steroid therapy for congenital adrenal hyperplasia.

Authors:  Giuseppe Scirè; Giorgio D'Anella; Laura Cristofori; Valentina Mazzuca; Stefano Cianfarani
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2007-06       Impact factor: 2.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.